Drug intelligence / Profile preview

gsk3862995b

Development stage: Phase 2
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

GSK3862995B is a monoclonal antibody developed by GSK to inhibit interleukin-33 (IL-33), a cytokine involved in inflammatory processes. Its primary mechanism of action is as an IL-33 inhibitor. The drug is being investigated for the treatment of chronic obstructive pulmonary disease (COPD) and is currently in Phase 1 clinical trials. The main goal of ongoing studies is to assess its safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics in both healthy participants and those with COPD.

Targets

IL33 (IL-33)

Beyond the preview

Go deeper on gsk3862995b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gsk3862995b.

Explore the full profile